Overall The UPMC Hillman Cancer Center (HCC) at University of Pittsburgh is a matrix cancer center, currently led by Robert L. Ferris, MD, PhD, who has served as Director of HCC since 2017. With funding from the National Cancer Institute and other peer- and non-peer-reviewed sources, HCC conducts impactful basic, clinical/translational, and population science research that is changing the way we detect, diagnose, and treat cancer. Through our research and community outreach efforts, we address the needs and disparities of cancer patients and those who are at risk of developing cancer in our 29-county western Pennsylvania catchment area, and through our strong efforts in educating and training new cancer researchers and clinicians, we are ensuring that those needs will continue to be met in the years to come. HCC integrates the expertise and resources of the University of Pittsburgh, a top-5 institution in NIH funding, and UPMC, one of our nation?s largest health care systems, to provide our 280 members with state-of-the-art facilities and equipment, and numerous opportunities for interaction and collaboration. Organized into 7 research programs focused on Cancer Biology, Genome Stability, Cancer Virology, Cancer Immunology and Immunotherapy, Cancer Therapeutics, Cancer Epidemiology and Prevention, and Biobehavioral Cancer Control, our members published over 4,000 articles and enrolled more than 12,700 adult and pediatric patients onto interventional clinical trials from 2014-2018. These efforts were enabled by our 10 shared resources and extensive infrastructure for supporting clinical research at central academic and community network sites. HCC is guided by an experienced Senior Leadership Team of Deputy and Associate Directors who join Dr. Ferris in overseeing our science and operations. With input from the leaders of our research programs and other key HCC members, this team sets the vision and develops the strategic plan for our future development, which includes a new HCC-wide Administrative Core for supporting team science. Over the next 5 years, HCC aims to: 1) expand upon our existing scientific strengths; 2) augment our shared resources; 3) develop and implement strategies for reducing cancer-related health problems in our catchment area population; 4) increase transdisciplinary research in topics that include tumor genomics and precision medicine, translational cancer immunotherapy, and environmental factors that impact cancers in our catchment area, and cancer and aging; 5) increase focus on education and learning at all levels of training; 6) implement precision medicine; 7) seek institutional and philanthropic funding to support faculty recruitment and retention, and the facilities and shared resources needed to advance our research initiatives; and 8) continue to engage in the dynamic planning and decision-making process that was instituted by our new Director.

Public Health Relevance

Overall The mission of the UPMC Hillman Cancer Center (HCC) is to reduce the burden of cancer in western Pennsylvania and the nation through research, patient care, education and outreach. Since its founding in 1985, HCC has been at the forefront in discovery and advancement of scientific findings that have led to new strategies for preventing, detecting, diagnosing, and treating cancer, and for addressing the health-related needs and well-being of cancer patients and survivors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA047904-32
Application #
10024334
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-09-10
Project End
2025-07-31
Budget Start
2020-09-04
Budget End
2021-07-31
Support Year
32
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15260
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications